PMV Pharmaceuticals, Inc. (PMVP): restructuring charge — PMV Pharma cuts workforce 30%, extends cash runway to end of 2026

PMV Pharmaceuticals, Inc.

Workforce reduction of ~30% to prioritize PC14586 development and streamline operations.
Unaudited cash, cash equivalents, and marketable securities of ~$229M as of Dec 31, 2023.
Expected non-recurring charges of ~$1.4M for employee severance and benefits, mainly in Q1 2024.
Cash runway now expected to extend to end of 2026 due to cost savings.
Registrational Phase 2 trial for PC14586 remains on track to initiate in Q1 2024.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

PMV Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.4 million (approximately 30% of the Company’s employees).

Type: restructuring
Charge: approximately $1.4 million
Headcount: approximately 30% of the Company’s employees

Exact text from the filing

development for its lead product candidate, PC14586. As a result of the reduction in force, the Company expects to incur aggregate non-recurring charges of approximately $1.4 million, consisting primarily of employee severance and benefit costs associated with the restructuring. The Company expects that most of these charges will be cash expenditures and that

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-010177

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.